# Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure

> **NCT02556450** · PHASE2 · COMPLETED · sponsor: **ACS Biomarker** · enrollment: 528 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Spironolacton

## Key facts

- **NCT ID:** NCT02556450
- **Lead sponsor:** ACS Biomarker
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-09-30
- **Final completion:** 2019-01-31
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2022-03-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02556450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02556450, "Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02556450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*